19 documents showing 1–19
Pfizer Inc. PFE
Pfizer squandered its $40bn COVID windfall on overpriced M&A while delivering almost none of the 15 promised blockbusters; the Board must hold management accountable.
N5
V4
C4
⌂
◫
”
⚑
Magellan Health, Inc. MGLN
Magellan destroyed $700M of value through failed acquisitions and three 2018 guidance cuts; Starboard's six-director slate will overhaul the board and run a parallel sale process at peer multiples.
N4
V2
C2
⌂
”
⚑
Date
Fund
Target
Thesis
Scores
Aug 18, 2025
Spruce Point Capital
iRhythm Technologies, Inc.
IRTC
Spruce Point argues iRhythm hid FDA-flagged Zio AT defects that killed patients and faces a DOJ cover-up probe; commoditized tech and an overstated asymptomatic market imply 40-70% downside.
N4
V3
Aug 11, 2025
Engine Capital
Avantor, Inc.
AVTR
Avantor's board has presided over five years of self-inflicted operational and capital-allocation failures; a refreshed board, cost discipline, buybacks and portfolio optimization can deliver 97-134% upside by 2027.
N4
V3
May 03, 2025
White Diamond Research
Pulse Biosciences
PLSE
PLSE's pivot to benign thyroid ablation repeats its failed dermatology playbook — tiny market, weak clinical data, revolving-door CEOs — and will trigger another stock collapse.
N3
V3
Jan 16, 2025
Spruce Point Capital
PROCEPT BioRobotics Corporation
PRCT
Procept trades at 14x revenue on a false 'all-prostates' TAM; Spruce Point sees channel-stuffing via DSOs at 130 days, no procedure growth, and 30-60% downside to $29-$54.
N4
V3
Oct 01, 2024
Starboard Value
Pfizer Inc.
PFE
Pfizer squandered its $40bn COVID windfall on overpriced M&A while delivering almost none of the 15 promised blockbusters; the Board must hold management accountable.
N5
V4
Feb 01, 2024
Ancora
Elanco Animal Health
ELAN
Elanco has destroyed billions under CEO Simmons and an insular classified board; replacing four directors at the 2024 AGM installs accountability and unlocks the animal-health turnaround.
N4
V4
Mar 28, 2023
Scorpion Capital
Harmony Biosciences Holdings
HRMY
Scorpion shorts HRMY: Wakix is a toxic, ineffective H3 antagonist propped up by sham foreign trials, an Insys-style kickback scheme, and off-label sales — collapse is imminent.
N4
V2
Feb 07, 2023
Spruce Point Capital
Progyny, Inc.
PGNY
PGNY is a $3.1bn fertility-benefits manager run by ex-WebMD/Medical Manager executives whose marketing claims, treatment model and 2023 growth are disputable, implying 60%-80% downside to $7-$14.
N5
V3
Apr 06, 2022
Spruce Point Capital
Stryker Corp.
SYK
Spruce Point exposes Stryker's FCPA-tainted accounting, failing acquisition roll-up and margin squeeze under CEO Lobo — Strong Sell with 35%-75% downside to $67-$174.50.
N4
V3
Jan 07, 2021
Scorpion Capital
Nevro Corp.
NVRO
Nevro is a failed one-trick pony at 15x sales: the pivotal SENZA trial was rigged, HF10 is a phony premise, explant rates run 22-33%, and kickbacks prop up what remains of sales.
N5
V3
Apr 22, 2020
Wolfpack Research
Inspire Medical Systems, Inc.
INSP
Inspire's surgical sleep-apnea implant is too invasive to ever scale — VA sales prove patients refuse it for free, while insiders have dumped $340M cashing out a fictional $10bn TAM story.
N4
V2
Oct 29, 2019
Spruce Point Capital
Hill-Rom Holdings, Inc.
HRC
Hill-Rom is a low-quality medical roll-up whose plateauing new products, exhausted margin expansion and aggressive accounting point to a 25-55% drop to $45-$75 per share.
N5
V4
Sep 16, 2019
White Diamond Research
Accelerate Diagnostics
AXDX
AXDX is a one-product company whose Pheno system is a flawed niche diagnostic — missed reagent targets, a looming Mayo-UCLA study failure, and cash burn point to 70% downside to a $6 price target.
N4
V2
Feb 22, 2019
Starboard Value
Magellan Health, Inc.
MGLN
Magellan destroyed $700M of value through failed acquisitions and three 2018 guidance cuts; Starboard's six-director slate will overhaul the board and run a parallel sale process at peer multiples.
N4
V2
May 07, 2018
Elliott Management
athenahealth, Inc.
ATHN
Elliott offers $160/share cash for athenahealth — a 27% premium valuing the company at ~$6.9bn — arguing chronic execution failures make going private the only path to realizing its HCIT potential.
N4
V2
Apr 08, 2016
Starboard Value
Depomed, Inc.
DEPO
Depomed's board is entrenching itself via a California-to-Delaware reincorporation and rejected Horizon's premium bid; Starboard seeks a special meeting to replace directors and explore a sale.
N3
V2
Apr 22, 2014
Pershing Square
Allergan, Inc.
AGN
Allergan shareholders should accept Valeant's bid: Valeant is an 'Outsider'-style acquirer (25x TSR under Pearson) whose lean R&D and platform M&A will compound Val-gan's value far beyond Allergan standalone.
N5
V3
Aug 01, 2013
Glenview
Health Management Associates
HMA
HMA's incumbent board destroyed 25% of independent value before rushing a sale to Community Health Systems; Glenview's Fresh Alternative board protects the deal and recovers upside.
N4
V2
Jul 01, 2013
Glenview
Health Management Associates
HMA
HMA's insular 17-year-tenure board drove a Lost Decade of <1% TSR; replace all directors with Glenview's blue-chip slate to fix governance, compensation, and capital allocation.
N5
V3